Corilagin enhances the anti-tumor activity of 5-FU by downregulating the expression of GRP 78

Simin Li,Xinquan Li,Xiliang Yang,Yumeng Lei,Mingxin He,Xiaochen Xiang,Qingming Wu,Hongyun Liu,Jiadun Wang,Qiang Wang
DOI: https://doi.org/10.1038/s41598-023-49604-1
IF: 4.6
2023-12-20
Scientific Reports
Abstract:Colorectal cancer is one of the most common malignancies worldwide. Although initially effective, patients who receive chemotherapy ultimately experience various complications and develop chemo-resistance, leading to cancer recurrence. Therefore, we aimed to find a drug with good efficacy and low toxicity that could enhance the treatment with 5-Fluorouracil (a commonly used clinical drug) and reduce its dosing. Corilagin, an anti-tumor natural product, has received widespread attention. Glucose regulated protein 78 (GRP78) is overexpressed in colorectal cancer cells and plays a key role in the proliferation, migration and drug resistance of cancer cells. Importantly, GRP78 can affect the apoptosis induced by 5-fluorouracil in CRC cells. In the present study, we determined the synergistic anti-tumor activity of the combination treatment by cell proliferation assay, apoptosis assay, fluorescent staining, cell cycle analysis, WB and PCR assays. This synergistic effect was associated with S-phase blockade, intracellular reactive oxygen species production and downregulation of GRP78. Taken together, our results indicate that Corilagin acts as a potentiator of 5-fluorouracil and may have therapeutic potential for patients with CRC.
multidisciplinary sciences
What problem does this paper attempt to address?